Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00006436 · OUTCOME

1 Year Overall Survival

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection · Source last updated 2026-08-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
1 year

What was measured

Overall survival is time from treatment start date until date of death or date last known alive.

Analysis population: One participant declined to participate before treatment started.

Groups in this outcome

Arm 1-Combination Chemo and Biological Therapy

Combination chemo and biological therapy Rituximab: 2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5 Filgrastim: Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle Etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride (EPOCH): combination chemotherapy: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm 1-Combination Chemo and Biological Therapy67

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm 1-Combination Chemo and Biological Therapy83.7Not reported71.091.2Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        71.0
        upper Limit
        91.2
        value
        83.7
denoms
  1. counts
    1. group Id
      OG000
      value
      67
    units
    Participants
description
Overall survival is time from treatment start date until date of death or date last known alive.
dispersion Type
95% Confidence Interval
groups
  1. description
    Combination chemo and biological therapy Rituximab: 2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5 Filgrastim: Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle Etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride (EPOCH): combination chemotherapy: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles
    id
    OG000
    title
    Arm 1-Combination Chemo and Biological Therapy
param Type
NUMBER
population Description
One participant declined to participate before treatment started.
reporting Status
POSTED
time Frame
1 year
title
1 Year Overall Survival
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice